INHIBRX BIOSCIENCES INC (INBX) Stock Analyst Ratings
NASDAQ:INBX - Nasdaq - US45720N1037 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 46% to INBX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 12.24. This target is -18.02% below the current price.
INBX was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about INBX.
In the previous month the buy percentage consensus was at a similar level.
INBX was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-05-15 | JMP Securities | Reiterate | Market Perform -> Market Perform |
| 2025-03-18 | Citizens Capital Markets | Reiterate | Market Perform -> Market Perform |
| 2025-01-22 | JMP Securities | Reiterate | Market Perform -> Market Perform |
| 2024-07-23 | JMP Securities | Initiate | Market Perform |
| 2024-01-23 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2023-11-20 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-08-23 | JMP Securities | Maintains | Outperform -> Outperform |
| 2023-05-10 | JMP Securities | Reiterate | Market Outperform |
| 2023-03-08 | JMP Securities | Maintains | Market Outperform |
| 2023-03-07 | Credit Suisse | Reiterate | Outperform |
| 2022-11-08 | Credit Suisse | Maintains | Outperform |
| 2022-10-05 | Evercore ISI Group | Maintains | Outperform |
| 2022-08-09 | Credit Suisse | Maintains | Outperform |
| 2022-03-02 | JMP Securities | Maintains | Market Outperform |
| 2021-11-10 | Credit Suisse | Maintains | Outperform |
| 2021-11-02 | JMP Securities | Maintains | Market Outperform |
| 2021-09-21 | JMP Securities | Initiate | Market Outperform |